From left: Botond Roska (IOB Director Molecular Research), Magdalena Renner...
From left: Botond Roska (IOB Director Molecular Research), Magdalena Renner (Head IOB Organoid Platform) and Cameron Cowan (Senior Researcher in the IOB Human Retinal Circuit Group)

Image credit: IOB.ch

News • Promising approach for eye diseases

Functional human retinas created in a dish

Scientists have generated accurate replications of human retinas in culture that can be used to pinpoint the specific types of cells affected by genetic eye diseases.

The culmination of a six-year effort, this achievement will accelerate progress in developing new therapies and was reported in Cell by a team led by Botond Roska at the Institute for Molecular and Clinical Ophthalmology Basel (IOB) and collaborators at the Novartis Institutes for BioMedical Research.

"The research addresses a fundamental unmet need, which is to develop model retinas that closely resemble the real organ," says Cameron Cowan, a senior researcher in the IOB Human Retinal Circuit Group and the paper's first author. "It opens up the possibility of developing treatments in a dish tailored to individual patients."

Photo
Retinal organoid - thin section

Image credit: IOB.ch

The retina is the part of eye that receives and organizes visual information. It contains millions of light-sensitive cells and nerves and has five distinct layers that collectively send signals to the brain so that people can see. The cultured retinas, which are called organoids, had been derived from pluripotent stem cells that were then coaxed to self-organize into this five-layered structure. The mature organoids could sense light at their surface layers, and they delivered visual impulses via synapses to the cell layers inside. Importantly, the IOB team developed a method that generates highly uniform retinal organoids by the thousands, providing a valuable resource for researchers around the world.

Upon assessing the organoids genetically, the team found that their transcriptomes (i.e., total gene read-outs), stabilized at a developed state containing most retinal cell types by week 38, which is also the average length of a human pregnancy. Then in a further characterization, IOB researchers compared the organoids to human retinas from multi-organ donors. Donated retinas will soon be damaged by a lack of blood flow and oxygen, so the team developed a way to keep them fresh. Using this method, the retinas retained light sensitivity and healthy functional circuitry for up to 16 hours. "Ours is the first publication showing light responses in post-mortem retinas," says IOB director and co-author Botond Roska. "This is clear evidence of an improved isolation procedure, since the retinas otherwise lose this ability."

The comparison revealed that cell-specific transcriptomes in maturing organoids and the real retinas become increasingly similar over time. Moreover, retinal diseases, the research showed, map to the same sorts of cells in the organoids and real retinas. Based on that finding, the IOB scientists made a significant contribution: They created a publicly-available atlas of transcriptomes for each retinal cell type.

Using that resource, researchers can now map diseases to retinal cells that they can also grow and study in a dish. The combined resources usher in a wealth of therapeutic opportunities. "You can grow high-quality retinal organoids derived from a patient's own pluripotent stem cells," says Magdalena Renner, Head of the IOB Human Organoid Platform, who also shares credits as the paper's first author. "And with the transcriptome atlas, you can find out where a disease gene is expressed, so you can deliver a gene therapy that will go in and fix it."


Source: Institute for Molecular and Clinical Ophthalmology Basel (IOB)

19.09.2020

More on the subject:
Read all latest stories

Related articles

Photo

News • Prevention of blood cancer

Research identifies new target that may prevent blood cancer

An international coalition of biomedical researchers has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their…

Photo

News • Making tumours susceptible to chemo

Breast cancer: target protein may hold key to therapy success

A rare variant of a protein present in nearly all human cells may hold the key to improving the effectiveness of breast cancer treatment, according to University of Manchester research.  

Photo

News • Insights into stem cell behaviour

Breast cancer: new mechanism of drug resistance discovered

Scientists in Italy discovered a new drug-resistance mechanism in breast cancer that leads to the formation of cancer stem cells. They also devised an experimental therapy to bypass or prevent this.

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Mass Spectrometry

Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Shimadzu Europa GmbH
Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Shimadzu Europa GmbH
Shimadzu – MALDImini-1

Research Use Only

Shimadzu – MALDImini-1

Shimadzu Europa GmbH
Subscribe to Newsletter